Last updated on October 2017

Long-Term Tolerability and Safety of HYQVIA/HyQvia in CIDP


Brief description of study

The purpose of this study is to assess the long-term safety, tolerability, and immunogenicity of the subcutaneous (SC) treatment with Immune Globulin Subcutaneous (IGSC) facilitated with recombinant human hyaluronidase (rHuPH20) (HYQVIA/HyQvia) in participants with chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) who have completed Baxalta Clinical Study Protocol 161403 Epoch 1 or Clinical Study Protocol 161601 without CIDP worsening.

Clinical Study Identifier: NCT02955355

.

Contact Investigators or Research Sites near you

Start Over

Please choose location

View all locations

Andras Nagy

Groupe Hospitalier Pellegrin - H pital Pellegrin
Bordeaux Cedex, France
  Connect »